» Articles » PMID: 15940625

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

Overview
Specialty Gastroenterology
Date 2005 Jun 9
PMID 15940625
Citations 758
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: In nonalcoholic fatty liver disease (NAFLD), the distinction between steatosis and steatohepatitis (NASH) and the assessment of the severity of the disease rely on liver histology alone. The aim of this study was to assess the sampling error of liver biopsy and its impact on the diagnosis and staging of NASH.

Methods: Fifty-one patients with NAFLD underwent percutaneous liver biopsy with 2 samples collected. The agreement between paired biopsy specimens was assessed by the percentage of discordant results and by the kappa reliability test.

Results: No features displayed high agreement; substantial agreement was only seen for steatosis grade; moderate agreement for hepatocyte ballooning and perisinusoidal fibrosis; fair agreement for Mallory bodies; acidophilic bodies and lobular inflammation displayed only slight agreement. Overall, the discordance rate for the presence of hepatocyte ballooning was 18%, and ballooning would have been missed in 24% of patients had only 1 biopsy been performed. The negative predictive value of a single biopsy for the diagnosis of NASH was at best 0.74. Discordance of 1 stage or more was 41%. Six of 17 patients with bridging fibrosis (35%) on 1 sample had only mild or no fibrosis on the other and therefore could have been under staged with only 1 biopsy. Intraobserver variability was systematically lower than sampling variability and therefore could not account for most of the sampling error.

Conclusions: Histologic lesions of NASH are unevenly distributed throughout the liver parenchyma; therefore, sampling error of liver biopsy can result in substantial misdiagnosis and staging inaccuracies.

Citing Articles

Deep phenotyping of patients with MASLD upon high-intensity interval training.

Houttu V, Boulund U, Troelstra M, Csader S, Stols-Goncalves D, Mak A JHEP Rep. 2025; 7(3):101289.

PMID: 40051412 PMC: 11883402. DOI: 10.1016/j.jhepr.2024.101289.


Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review.

Garg S, Varghese M, Shaik F, Jatin F, Sachdeva D, Wafa Eranhikkal F Cureus. 2025; 17(2):e78421.

PMID: 40046382 PMC: 11881788. DOI: 10.7759/cureus.78421.


Optimization of regions of interest sampling strategies for proton density fat-fraction MRI of hepatic steatosis before liver transplantation in ex vivo livers.

Chen G, Tang H, Yang Y, Zhou L, Wang Q, Hu D Heliyon. 2025; 11(4):e40146.

PMID: 40028590 PMC: 11872435. DOI: 10.1016/j.heliyon.2024.e40146.


Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels.

Kjaer M, Jorgensen A, Fjelstrup S, Dupont D, Bus C, Eriksen P Biomolecules. 2025; 15(2).

PMID: 40001558 PMC: 11852711. DOI: 10.3390/biom15020255.